|
Federal Register
Notices > Importers >
Cerilliant Corporation
FR Doc E6-1023 [Federal Register: January 27, 2006 (Volume 71, Number 18)]
[Notices] [Page 4612-4613] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr27ja06-86]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a
registration under this Section to a bulk manufacturer of a controlled substance
in Schedule I or II and prior to issuing a regulation under 21
U.S.C.
952(a)(2)(B) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on
August 17, 2005, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock,
Texas 78664, made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of the basic classes of controlled
substances listed in Schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
Gamma hydroxybutyric acid (2010)
|
I
|
|
Ibogaine (7260)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
Etorphine (9056)
|
I
|
|
Heroin (9200)
|
I
|
|
Pholcodine (9314)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Oxymorphone (9652)
|
II
|
The company plans to import small quantities of the listed controlled
[[Page 4613]]
substances for the manufacture of analytical reference standards.
Any manufacturer who is presently, or is applying to be, registered with DEA
to manufacture such basic classes of controlled substances may file comments or
objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections being sent via regular mail may be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL);
or any being sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis
Highway, Alexandria, Virginia 22301; and must be filed no later than February
27, 2006.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a
previous notice published in the Federal Register on September 23, 1975, (40 FR
43745-46), all applicants for registration to import a basic class of any
controlled substance listed in Schedule I or II are, and will continue to be
required to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21
U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: January 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6-1023 Filed 1-26-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|